Equillium shares are trading lower after the company announced Ono Pharmaceutical has made the business decision to allow the expiration of its option to acquire Equillium's rights to Itolizumab
Portfolio Pulse from Benzinga Newsdesk
Equillium's shares dropped after Ono Pharmaceutical decided not to exercise its option to acquire rights to Itolizumab from Equillium.
October 31, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Equillium's stock is negatively impacted as Ono Pharmaceutical decided not to acquire rights to Itolizumab, leading to a drop in share price.
The decision by Ono Pharmaceutical not to acquire rights to Itolizumab is a setback for Equillium, as it likely affects future revenue expectations and partnership opportunities, leading to a negative market reaction.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90